Skip to main content
. 2023 Nov 30;21:870. doi: 10.1186/s12967-023-04749-5

Table 2.

Several variables of participants, by quartile of total VB2 intake

Variables Q1, n = 737 (25%)1 Q2, n = 603 (25%)1 Q3, n = 528 (25%)1 Q4, n = 458 (25%)1 P2
Total VB2 intake 1.29 (1.07, 1.47) 2.06 (1.89, 2.28) 3.18 (2.89, 3.46) 5.26 (4.41, 22.01)
AFT 17.00 (13.00, 20.00) 18.00 (14.00, 21.00) 18.00 (14.00, 22.00) 19.00 (15.00, 23.00)  < 0.001
CERAD Trial 1 Recall 5.00 (4.00, 6.00) 5.00 (4.00, 6.00) 5.00 (4.00, 6.00) 5.00 (4.00, 6.00) 0.009
CERAD Trial 2 Recall 7.00 (6.00, 8.00) 7.00 (6.00, 8.00) 7.00 (6.00, 8.00) 7.00 (6.00, 9.00) 0.080
CERAD Trial 3 Recall 8.00 (7.00, 9.00) 8.00 (7.00, 9.00) 8.00 (7.00, 9.00) 8.00 (7.00, 9.00) 0.263
CERAD total 20.00 (17.00, 23.00) 20.00 (17.00, 23.00) 20.00 (17.00, 23.00) 20.00 (18.00, 23.30) 0.098
CERAD Delayed Recall 6.00 (5.00, 8.00) 7.00 (5.00, 8.00) 6.00 (5.00, 8.00) 7.00 (5.00, 8.00) 0.545
DSST 51.97 (37.00, 62.00) 51.00 (42.00, 63.00) 54.00 (42.89, 65.27) 56.00 (47.00, 66.00)  < 0.001
ALT 18.00 (15.00, 24.00) 19.00 (16.00, 25.00) 20.00 (17.00, 26.00) 21.00 (17.00, 26.00)  < 0.001
AST 22.00 (19.00, 27.00) 22.00 (20.00, 27.00) 24.00 (21.00, 27.00) 25.00 (22.00, 28.00)  < 0.001
Cholesterol 4.83 (4.24, 5.77) 4.89 (4.09, 5.60) 4.89 (4.06, 5.70) 4.94 (4.19, 5.66) 0.672

1Median (IQR)

2Wilcoxon rank-sum test for complex survey samples